Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.

by James B Gilmore, Anthony D Kelleher, David A Cooper, John M Murray
Published 2013-01-01

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

by Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper
Published 2014-01-01

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.

by Allison Martin, Janaki Amin, Sean Emery, David Baker, Andrew Carr, David A Cooper, Mark Bloch, STEAL Study Group
Published 2011-01-01

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

by Hila Haskelberg, Damien V Cordery, Janaki Amin, Anthony D Kelleher, David A Cooper, Sean Emery, STEAL Study Group
Published 2014-01-01

Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing

by Chantelle Ahlenstiel, Catalina Mendez, Steven T H Lim, Katherine Marks, Stuart Turville, David A Cooper, Anthony D Kelleher, Kazuo Suzuki
Published 2015-01-01

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

by Karen Schneider, Chidi Nwizu, Richard Kaplan, Jonathan Anderson, David P Wilson, Sean Emery, David A Cooper, Mark A Boyd
Published 2013-01-01

Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.

by Alexander Hoare, Stephen J Kerr, Kiat Ruxrungtham, Jintanat Ananworanich, Matthew G Law, David A Cooper, Praphan Phanuphak, David P Wilson
Published 2010-06-01

HIV dynamics linked to memory CD4+ T cell homeostasis.

by John M Murray, John Zaunders, Sean Emery, David A Cooper, William J Hey-Nguyen, Kersten K Koelsch, Anthony D Kelleher
Published 2017-01-01

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

by Steven N Reuland, Nathaniel B Goldstein, Katie A Partyka, David A Cooper, Mayumi Fujita, David A Norris, Yiqun G Shellman
Published 2011-01-01

Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLE...

by Kathy Petoumenos, Robin Huang, Jennifer Hoy, Mark Bloch, David J Templeton, David Baker, Michelle Giles, Matthew G Law, David A Cooper
Published 2017-01-01

Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

by Yu Ming Paul Lam, Kristin L McBride, Janaki Amin, Damien V Cordery, Anthony D Kelleher, David A Cooper, Kersten K Koelsch
Published 2012-01-01

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.

by Mykola Pinkevych, Stephen J Kent, Martin Tolstrup, Sharon R Lewin, David A Cooper, Ole S Søgaard, Thomas A Rasmussen, Anthony D Kelleher, Deborah Cromer, Miles P Davenport
Published 2016-08-01

Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing

by Kazuo Suzuki, Shinichiro Hattori, Katherine Marks, Chantelle Ahlenstiel, Yosuke Maeda, Takaomi Ishida, Michelle Millington, Maureen Boyd, Geoff Symonds, David A Cooper, Seiji Okada, Anthony D Kelleher
Published 2013-01-01

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomi...

by David A Cooper, Damien V Cordery, Roberto Zajdenverg, Kiat Ruxrungtham, Keikawus Arastéh, Frank Bergmann, José L de Andrade Neto, Joseph Scherer, Ricardo L Chaves, Patrick Robinson, study team
Published 2016-01-01

Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.

by Denise C Hsu, Stephen J Kerr, Thatri Iampornsin, Sarah L Pett, Anchalee Avihingsanon, Parawee Thongpaeng, John J Zaunders, Sasiwimol Ubolyam, Jintanat Ananworanich, Anthony D Kelleher, David A Cooper
Published 2013-01-01

Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection.

by Sarah C Sasson, John J Zaunders, Nabila Seddiki, Michelle Bailey, Kristin McBride, Kersten K Koelsch, Kate M Merlin, Don E Smith, David A Cooper, Anthony D Kelleher
Published 2012-01-01

The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study.

by Nan Phyu Sin Toe Myint, Ne Myo Aung, Myint Soe Win, Thu Ya Htut, Anna P Ralph, David A Cooper, Myo Lwin Nyein, Mar Mar Kyi, Josh Hanson
Published 2018-01-01

Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART.

by Alan Winston, Rebekah Puls, Stephen J Kerr, Chris Duncombe, Patrick Li, John M Gill, Reshmie Ramautarsing, Simon D Taylor-Robinson, Sean Emery, David A Cooper, ALTAIR Study Group
Published 2015-01-01

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport
Published 2015-07-01

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport
Published 2016-08-01